Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Patient Dropouts | 1 | 2019 | 66 | 0.570 |
Why?
|
| Early Detection of Cancer | 3 | 2020 | 486 | 0.540 |
Why?
|
| Barrett Esophagus | 3 | 2026 | 169 | 0.520 |
Why?
|
| Colonic Polyps | 2 | 2024 | 88 | 0.380 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 521 | 0.380 |
Why?
|
| Decision Making | 1 | 2019 | 981 | 0.350 |
Why?
|
| Esophageal Neoplasms | 2 | 2026 | 348 | 0.310 |
Why?
|
| Hypertension | 1 | 2017 | 1276 | 0.270 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2026 | 41 | 0.230 |
Why?
|
| Primary Health Care | 4 | 2024 | 1736 | 0.230 |
Why?
|
| Residence Characteristics | 2 | 2019 | 375 | 0.220 |
Why?
|
| Wound Infection | 1 | 2026 | 60 | 0.220 |
Why?
|
| Periodontics | 1 | 2025 | 11 | 0.220 |
Why?
|
| Students, Dental | 1 | 2025 | 20 | 0.220 |
Why?
|
| Education, Dental | 1 | 2025 | 38 | 0.210 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2024 | 73 | 0.200 |
Why?
|
| Esophagoscopy | 1 | 2026 | 223 | 0.200 |
Why?
|
| Morals | 1 | 2025 | 79 | 0.200 |
Why?
|
| Physicians, Women | 1 | 2025 | 90 | 0.200 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 169 | 0.190 |
Why?
|
| Comprehension | 1 | 2025 | 186 | 0.190 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 251 | 0.180 |
Why?
|
| Respiratory Rate | 1 | 2022 | 24 | 0.180 |
Why?
|
| Sunlight | 1 | 2022 | 78 | 0.180 |
Why?
|
| Opiate Substitution Treatment | 1 | 2024 | 189 | 0.170 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 868 | 0.170 |
Why?
|
| Respiration | 1 | 2022 | 207 | 0.170 |
Why?
|
| Colonoscopy | 1 | 2024 | 264 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2026 | 926 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2026 | 1062 | 0.160 |
Why?
|
| Buprenorphine | 1 | 2024 | 192 | 0.160 |
Why?
|
| Water Purification | 1 | 2022 | 156 | 0.160 |
Why?
|
| Gastroesophageal Reflux | 1 | 2022 | 237 | 0.150 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 1154 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2026 | 1150 | 0.140 |
Why?
|
| Unemployment | 1 | 2019 | 43 | 0.140 |
Why?
|
| Clinical Competence | 2 | 2025 | 1247 | 0.140 |
Why?
|
| Transportation | 1 | 2019 | 57 | 0.140 |
Why?
|
| Loneliness | 1 | 2019 | 69 | 0.130 |
Why?
|
| Burnout, Professional | 1 | 2025 | 488 | 0.130 |
Why?
|
| Income | 1 | 2019 | 203 | 0.130 |
Why?
|
| Wounds and Injuries | 1 | 2026 | 962 | 0.130 |
Why?
|
| Dominican Republic | 1 | 2017 | 29 | 0.130 |
Why?
|
| Noncommunicable Diseases | 1 | 2017 | 21 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 444 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 605 | 0.120 |
Why?
|
| Morphine | 1 | 2017 | 169 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 588 | 0.110 |
Why?
|
| Developing Countries | 1 | 2017 | 317 | 0.110 |
Why?
|
| Linear Models | 1 | 2017 | 849 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2018 | 321 | 0.110 |
Why?
|
| Internet | 1 | 2019 | 693 | 0.100 |
Why?
|
| Humans | 18 | 2026 | 145750 | 0.100 |
Why?
|
| Communication | 1 | 2020 | 976 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1327 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2018 | 610 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 6084 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 303 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 1196 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 1101 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2017 | 782 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2017 | 1782 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1372 | 0.080 |
Why?
|
| Research Design | 2 | 2026 | 1139 | 0.080 |
Why?
|
| Female | 10 | 2026 | 79025 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 2967 | 0.070 |
Why?
|
| Virginia | 2 | 2019 | 57 | 0.070 |
Why?
|
| Male | 9 | 2026 | 72992 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 2190 | 0.070 |
Why?
|
| Aged | 6 | 2026 | 26212 | 0.060 |
Why?
|
| Risk Factors | 4 | 2026 | 10916 | 0.060 |
Why?
|
| Ukraine | 1 | 2026 | 37 | 0.060 |
Why?
|
| Middle Aged | 6 | 2026 | 36297 | 0.060 |
Why?
|
| Warfare | 1 | 2026 | 99 | 0.060 |
Why?
|
| North America | 1 | 2026 | 303 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 5921 | 0.050 |
Why?
|
| Gene-Environment Interaction | 1 | 2026 | 180 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2026 | 413 | 0.050 |
Why?
|
| Time Factors | 2 | 2026 | 7133 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2024 | 133 | 0.050 |
Why?
|
| Formative Feedback | 1 | 2024 | 36 | 0.050 |
Why?
|
| Computer-Assisted Instruction | 1 | 2024 | 70 | 0.050 |
Why?
|
| Learning Curve | 1 | 2024 | 71 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2026 | 8075 | 0.050 |
Why?
|
| Plastics | 1 | 2022 | 50 | 0.050 |
Why?
|
| Recurrence | 1 | 2026 | 1139 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2026 | 1330 | 0.040 |
Why?
|
| Water Microbiology | 1 | 2022 | 85 | 0.040 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 203 | 0.040 |
Why?
|
| Motion | 1 | 2022 | 95 | 0.040 |
Why?
|
| Colorado | 2 | 2024 | 4556 | 0.040 |
Why?
|
| Disinfection | 1 | 2022 | 131 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 1474 | 0.040 |
Why?
|
| Perception | 1 | 2022 | 378 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 176 | 0.040 |
Why?
|
| American Heart Association | 1 | 2021 | 358 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 408 | 0.040 |
Why?
|
| Incidence | 1 | 2026 | 2933 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2020 | 536 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 187 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2022 | 835 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2022 | 860 | 0.030 |
Why?
|
| Altitude | 1 | 2022 | 463 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2024 | 868 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 2399 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2017 | 120 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2026 | 5428 | 0.030 |
Why?
|
| Anesthetics | 1 | 2017 | 100 | 0.030 |
Why?
|
| Pandemics | 1 | 2024 | 1711 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2017 | 203 | 0.030 |
Why?
|
| Telemedicine | 1 | 2024 | 963 | 0.030 |
Why?
|
| Adult | 3 | 2025 | 40867 | 0.030 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 183 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2025 | 1269 | 0.030 |
Why?
|
| Anesthesia | 1 | 2017 | 257 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2024 | 17322 | 0.020 |
Why?
|
| Pneumonia | 1 | 2018 | 636 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2018 | 1810 | 0.020 |
Why?
|
| United States | 2 | 2020 | 16122 | 0.020 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 375 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3634 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2019 | 1676 | 0.020 |
Why?
|
| Length of Stay | 1 | 2017 | 1350 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2026 | 11793 | 0.020 |
Why?
|
| Exercise | 1 | 2022 | 2203 | 0.020 |
Why?
|
| Vaccination | 1 | 2018 | 1428 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 1101 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2447 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2018 | 2344 | 0.020 |
Why?
|
| Obesity | 1 | 2018 | 3118 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 14250 | 0.010 |
Why?
|